Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the united kingdom randomised, controlled open-label, platform adaptive trial (SSRN, 2022)

(untitled) - Butler, C; Hobbs, FDR; Gbinigie, O; Rahman, NM; Hayward, G; Richards, D; Dorward, J; Lowe, D; Standing, JF; Breuer, J; Khoo, S; Petrou, S; et al.